Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.




The epicardium, which orchestrates coronary vessel development, is partially reactivated post-myocardial infarction to facilitate neovascularisation and regeneration. However, a key limitation to the efficiency of epicardium-based repair is the low proportion of cells that undergo epithelial-mesenchymal transition (EMT) to contribute to the pool of active progenitors at the infarct site. We identified sulfatases as enzymes that control the sensitivity of epicardial cells to the growth factors that drive EMT. The CRM pump priming award enabled the generation of global and conditional knockout lines, which are now being used to validate sulfatases as key regulators of EMT and putative targets to therapeutically enhance EMT and advance epicardium-based regenerative strategies.